Tag - LXRX

Developments

Lexicon signs exclusive licencing agreement with Viatris for sotagliflozin outside U.S. and Europe

Lexicon Pharmaceuticals (NASDAQ:LXRX) has announced that Viatris (NASDAQ:VTRS) obtained an exclusive license from Lexicon to commercialize sotagliflozin across all indications outside the U.S. and Europe, in exchange...

October 17, 2024

Developments

Lexicon gets FDA fast track designation for diabetic peripheral neuropathic pain

Lexicon Pharmaceuticals’ (NASDAQ:LXRX) LX9211 received FDA fast track designation for the treatment of diabetic peripheral neuropathic pain. The company is currently enrolling patients with diabetic peripheral...

December 11, 2020

Developments

Lexicon sotagliflozin meets primary endpoint in four Phase 3 studies

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported topline data from four Phase 3 studies, each of which demonstrated that sotagliflozin significantly reduced A1C levels in patients with Type 2 diabetes (T2D). Sotagliflozin...

July 21, 2020

Developments

Lexicon Pharmaceuticals’ reports topline Phase 3 data for Type 2 diabetes drug

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported topline data from its Phase 3 study of sotagliflozin for the treatment of Type 2 diabetes (T2D). Sotagliflozin is an oral dual inhibitor of sodium-glucose co-transporter...

December 20, 2019

Tag - LXRX

Lexicon signs exclusive licencing agreement with Viatris for sotagliflozin outside U.S. and Europe

Lexicon gets FDA fast track designation for diabetic peripheral neuropathic pain

Lexicon sotagliflozin meets primary endpoint in four Phase 3 studies

Lexicon Pharmaceuticals’ reports topline Phase 3 data for Type 2 diabetes drug

General

More